MedTrace Logo

Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.

NCT05718531 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-02-08

No results posted yet for this study

Summary

1. To evaluate short and intermediate clinical outcome of different anti-thrombotic regimens on major adverse cardiac events (MACE) and quality of life in coronary artery ectasia patients.
2. To evaluate role of P-selectin as a marker of cardiovascular risk in coronary artery ectasia.

Conditions

  • Coronary Artery Ectasia

Interventions

DRUG

Rivaroxaban 2.5 Mg Oral Tablet twice daily

effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.

DRUG

Clopidogrel 75 Mg Oral Tablet

Used as control group in 2nd arm and 5th arm

DRUG

Aspirin tablet 75 mg

Used as control group in 2nd arm and 5th arm

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hamdy S. Mohammad, MD · Assiut University

  • Mahmoud A. Abdallah, MD · Assiut University

  • Aly M. Tohamy, MD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-02-28
Completion
2025-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05718531 on ClinicalTrials.gov